Immune-related pancreatitis secondary to nivolumab in a patient with recurrent lung adenocarcinoma: A case report

Lung Cancer

Volumn 99, Issue , 2016, Pages 148-150

  Ikeuchi, Kazuhiko ^a   Okuma, Yusuke ^a   Tabata, Taku ^a  

^a TOKYO METROPOLITAN KOMAGOME HOSPITAL   (Japan)

Author keywords

Immune checkpoint inhibitor; Immune related pancreatitis; Lung adenocarcinoma; Nivolumab

Indexed keywords

ALANINE AMINOTRANSFERASE; AMYLASE; ASPARTATE AMINOTRANSFERASE; CREATININE; INFUSION FLUID; NIVOLUMAB; PREDNISONE; TRIACYLGLYCEROL LIPASE; ULINASTATIN; IMMUNOLOGICAL ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY;

AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; AMYLASE BLOOD LEVEL; ANOREXIA; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BACKACHE; CANCER RECURRENCE; CASE REPORT; CREATININE BLOOD LEVEL; DIFFUSION WEIGHTED IMAGING; DRUG DOSE INCREASE; FEMALE; FOLLOW UP; HUMAN; IMMUNE RELATED PANCREATITIS; LUNG ADENOCARCINOMA; LYMPH NODE METASTASIS; MAGNETIC RESONANCE CHOLANGIOPANCREATOGRAPHY; MULTIPLE CYCLE TREATMENT; PANCREATITIS; PRIORITY JOURNAL; TRIACYLGLYCEROL LIPASE BLOOD LEVEL; VOMITING; ADENOCARCINOMA; COMPLICATION; LUNG TUMOR; NUCLEAR MAGNETIC RESONANCE IMAGING; TREATMENT OUTCOME; TUMOR RECURRENCE; X-RAY COMPUTED TOMOGRAPHY;

ADENOCARCINOMA; AGED; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS, IMMUNOLOGICAL; FEMALE; HUMANS; LUNG NEOPLASMS; MAGNETIC RESONANCE IMAGING; NEOPLASM RECURRENCE, LOCAL; PANCREATITIS; PREDNISONE; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME;

EID: 84978427272     PISSN: 01695002     EISSN: 18728332     Source Type: Journal    
DOI: 10.1016/j.lungcan.2016.07.001     Document Type: Article

References (14)

1. [1] Melosky, B., Chu, Q., Juergens, R., Leighl, N., McLeod, D., Hirsh, V., Pointed progress in second-Line advanced non-Small-Cell lung cancer: the rapidly evolving field of checkpoint inhibition. J. Clin. Oncol. 34 (2016), 1676–1688.
2. [2] Brahmer, J., Reckamp, K.L., Baas, P., Crino, L., Eberhardt, W.E., Poddubskaya, E., Antonia, S., Pluzanski, A., Vokes, E.E., Holgado, E., Waterhouse, D., Ready, N., Gainor, J., Aren Frontera, O., Havel, L., Steins, M., Garassino, M.C., Aerts, J.G., Domine, M., Paz-Ares, L., Reck, M., Baudelet, C., Harbison, C.T., Lestini, B., Spigel, D.R., Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N. Engl. J. Med. 373 (2015), 123–135.
3. [3] Borghaei, H., Paz-Ares, L., Horn, L., Spigel, D.R., Steins, M., Ready, N.E., Chow, L.Q., Vokes, E.E., Felip, E., Holgado, E., Barlesi, F., Kohlhaufl, M., Arrieta, O., Burgio, M.A., Fayette, J., Lena, H., Poddubskaya, E., Gerber, D.E., Gettinger, S.N., Rudin, C.M., Rizvi, N., Crino, L., Blumenschein, G.R. Jr., Antonia, S.J., Dorange, C., Harbison, C.T., Graf Finckenstein, F., Brahmer, J.R., Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N. Engl. J. Med. 373 (2015), 1627–1639.
4. [4] Champiat, S., Lambotte, O., Barreau, E., Belkhir, R., Berdelou, A., Carbonnel, F., Cauquil, C., Chanson, P., Collins, M., Durrbach, A., Ederhy, S., Feuillet, S., Francois, H., Lazarovici, J., Le Pavec, J., De Martin, E., Mateus, C., Michot, J.M., Samuel, D., Soria, J.C., Robert, C., Eggermont, A., Marabelle, A., Management of immune checkpoint blockade dysimmune toxicities: a collaborative position paper. Ann. Oncol. 27 (2016), 559–574.
5. [5] Freeman-Keller, M., Kim, Y., Cronin, H., Richards, A., Gibney, G., Weber, J.S., Nivolumab in resected and unresectable metastatic melanoma: characteristics of immune-related adverse events and association with outcomes. Clin. Cancer Res. 22 (2016), 886–894.
6. [6] Raedler, L.A., Opdivo (Nivolumab): second PD-1 inhibitor receives FDA approval for unresectable or metastatic melanoma. Am. Health Drug Benefits 8 (2015), 180–183.
7. [7] Uchikoshi, F., Yang, Z.D., Rostami, S., Yokoi, Y., Capocci, P., Barker, C.F., Naji, A., Prevention of autoimmune recurrence and rejection by adenovirus-mediated CTLA4Ig gene transfer to the pancreatic graft in BB rat. Diabetes 48 (1999), 652–657.
8. [8] Di Giacomo, A.M., Danielli, R., Guidoboni, M., Calabro, L., Carlucci, D., Miracco, C., Volterrani, L., Mazzei, M.A., Biagioli, M., Altomonte, M., Maio, M., Therapeutic efficacy of ipilimumab, an anti-CTLA-4 monoclonal antibody, in patients with metastatic melanoma unresponsive to prior systemic treatments: clinical and immunological evidence from three patient cases. Cancer Immunol. Immunother. 58 (2009), 1297–1306.
9. [9] Alabed, Y.Z., Aghayev, A., Sakellis, C., Van den Abbeele, A.D., Pancreatitis secondary to anti-programmed death receptor 1 immunotherapy diagnosed by FDG PET/CT. Clin. Nucl. Med. 40 (2015), e528–529.
10. [10] Hofmann, L., Forschner, A., Loquai, C., Goldinger, S.M., Zimmer, L., Ugurel, S., Schmidgen, M.I., Gutzmer, R., Utikal, J.S., Goppner, D., Hassel, J.C., Meier, F., Tietze, J.K., Thomas, I., Weishaupt, C., Leverkus, M., Wahl, R., Dietrich, U., Garbe, C., Kirchberger, M.C., Eigentler, T., Berking, C., Gesierich, A., Krackhardt, A.M., Schadendorf, D., Schuler, G., Dummer, R., Heinzerling, L.M., Cutaneous, gastrointestinal, hepatic, endocrine, and renal side-effects of anti-PD-1 therapy. Eur. J. Cancer 60 (2016), 190–209.
11. [11] Irie, H., Honda, H., Baba, S., Kuroiwa, T., Yoshimitsu, K., Tajima, T., Jimi, M., Sumii, T., Masuda, K., Autoimmune pancreatitis: CT and MR characteristics. AJR Am. J. Roentgenol. 170 (1998), 1323–1327.
12. [12] Spain, L., Diem, S., Larkin, J., Management of toxicities of immune checkpoint inhibitors. Cancer Treat. Rev. 44 (2016), 51–60.
13. [13] Administration USFaD. OPDIVO (nivolumab9 Injection label) http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/125554lbl.pdf.
14. [14] Eigentler, T.K., Hassel, J.C., Berking, C., Aberle, J., Bachmann, O., Grunwald, V., Kahler, K.C., Loquai, C., Reinmuth, N., Steins, M., Zimmer, L., Sendl, A., Gutzmer, R., Diagnosis, monitoring and management of immune-related adverse drug reactions of anti-PD-1 antibody therapy. Cancer Treat. Rev. 45 (2016), 7–18.